Adavosertib is a tyrosine kinase WEE1 inhibitor used to improve the outcome in triple-negative breast cancer60, vinorelbine is an agent to treat NSCLC and breast cancer61, and capivasertib is AKT inhibitor used in the treatment of breast cancer62. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.